Skip to main content

Table 1 Baseline characteristics of the study population (n = 58)

From: Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients

Patient characteristics

Resection (n = 15)

Non-resection (n = 43)

Total (n = 58)

p-value

Age (years)

60.0 ± 10.5

62.8 ± 8.4

62.1 ± 9.0

0.292

Male, n (%)

6 (40.0%)

28 (65.1%)

34 (58.6%)

0.163

ECOG score, n (%)

   

0.531

 0

8 (53.3%)

17 (39.5%)

25 (43.1%)

 

 1

7 (46.7%)

26 (60.5%)

33 (56.9%)

 

DM, n (%)

6 (40.0%)

20 (46.5%)

26 (44.8%)

0.892

Tumor size (cm)

3.7 ± 0.7

3.9 ± 1.5

3.8 ± 1.3

0.434

Tumor location, n (%)

   

0.542

 Head/neck

8 (53.3%)

31 (72.1%)

39 (67.2%)

 

 Body/tail

7(46.7%)

12 (27.9%)

19 (32.8%)

 

Vessel invasion, n (%)

   

0.266

 Artery

2 (13.3%)

9 (20.9%)

11 (19.0%)

 

 Vein

0 (0.0%)

5 (11.6%)

5 (8.6%)

 

 Both

13 (86.7%)

29 (67.4%)

42 (72.4%)

 

CA 19–9 (U/mL)

576 ± 1,220

963 ± 1,833

863 ± 1,695

0.452

CEA (ng/mL)

9.2 ± 19.3

5.4 ± 10.1

6.4 ± 13.0

0.469

FOLFIRINOX cycles [median (range)]

11 (2–16)

8 (1–20)

9 (1–20)

0.193

 ≥ 6 cycles

14 (93.3%)

33 (76.7%)

47 (81.0%)

0.304

cRDI (%)

72.6 ± 12.4

66.4 ± 15.2

68.0 ± 14.7

0.164

 ≥ 70%

8 (53.3%)

21 (48.8%)

29 (50.0%)

1.000

BMI (kg/m2)

22.7 ± 2.6

21.3 ± 3.0

21.7 ± 2.9

0.110

SM area (cm2)

107.4 ± 26.6

113.3 ± 24.4

111.8 ± 24.9

0.435

AT area (cm2)

211.4 ± 66.3

198.8 ± 91.9

202.1 ± 85.6

0.627

  1. The data are presented as mean ± standard deviation or n (%)
  2. ECOG Eastern Cooperative Oncology Group, DM diabetes mellitus, CA19-9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, cRDI corrected relative dose intensity, BMI body mass index, SM skeletal muscle, AT adipose tissue